The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance

British Journal of Cancer

Volumn 75, Issue 6, 1997, Pages 804-809

  Johnston, Srd ^a   Riddler, S ^b   Haynes, B P ^c   A'Hern, R ^d   Smith, I E ^b   Jarman, M ^a   Dowsett, M ^b  

^a Departments of Academic Biochemistry

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c Biological Services Unit

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Acquired resistance; Breast cancer; Idoxifene; Tamoxifen

Indexed keywords

ANTIESTROGEN; ESTRADIOL; IDOXIFENE; TAMOXIFEN;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 0031039798     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.144     Document Type: Article

References (27)

1. Chander SK, McCague R, Luqmani Y, Newton C, Dowsett M, Jarman M and Coombes RC (1991) Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analoques of the antioestrogen tamoxifen for the treatment of breast cancer. Cancer Res 51: 5851-5858
2. Coombes RC, Haynes BP, Dowsett M, Qugley M, English J, Judson IR, Griggs LJ, Potter GA, McCague R and Jarman M (1995) Idoxifene: report of a phase I study in patients with metastatic breast cancer. Cancer Res 55: 1070-1074
3. Daniel P, Gaskell SJ, Bishop H, Campbell C and Robertson RI (1981) Détermination of tamoxifen and biologically active metabolites in human breast tumours and plasma. Eur J Cancer Clin Oncol 17: 1183-1189
4. De Vos D, Siée PHTJ, Stevenson D and Briggs LJ (1992) Serum elimination half-life of tamoxifen and its metabolities in patients with advanced breast cancer. Cancer Chemother Pharamacol 31: 76-78
5. Dowsett M. Johnston SRD, Iveson TJ and Smith IE (1995) Response to pure antioestrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet 345: 525
6. Gottardis M and Jordan VC (1988) Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antioestrogen administration. Cancer 48:5183-5187
7. Gottardis MM, Robinson SP and Jordan VC (1988) Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 30: 311-314
8. Gottardis MM, Jiang S-Y, Jeng M-H and Jordan VC (1989) Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49: 4090-4093
9. Haynes BP, Parr IB, Griggs LJ and Jarman M (1991) Metabolism and pharmacokinetics of pyrroIidino-4-iodotamoxifen in the rat. Breast Cancer Res Treat 19: 174(A72)
10. Howell A, De Friend D, Robertson J, Blarney R and Walton P (1995) Response to the pure antioestrogen ICI 182,780 in tamoxifen resistant breast cancer. Lancet 345: 29-30
11. Howell A, Dodwell DJ, Laidlaw I, Anderson H and Andersen E (1990) Tamoxifen as an agonist for metastatic breast cancer. In Endocrine Therapy of Breast Cancer, Goldhirsch A (éd.), pp. 49-58 Springer: New York
12. Johnston SRD, Haynes BP, Sacks NPM, McKinna JA, Griggs LJ, Jarman M, Baum M, Smith IE and Dowsett M (1993) Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human breast cancer. Breast Cancer Res Treat 28: 241-250
13. Jordan VC, Bain RR, Brown RR, Gosden B and Santos MA (1983) Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Res 43: 1446-1450
14. Lyman SD and Jordan VC (1985) Metabolism of tamoxifen and its uterotrophic activity. Biochem Pharmacol 34: 2787-2794
15. McCague R (1986) Halogenated tamoxifens. British Patent Application No 8621908
16. McCague R, Leclercq G, Legros N, Goodman J, Blackburn GM, Jarman M, et al. ( 1989) Derivatives of tamoxifen; dependence of antioestrogenicity on the 4-substituent. J Med Chem 32: 2527-2533
17. McCague R, Parr IB, Leclercq G, Leung O-T and Jarman M ( 1990n) Metabolism of tamoxifen by isolated rat hepatocytes; identification of the glucuronide of 4-hydroxytamoxifen. Biochem Pharmacol 39: 1459-1465
18. McCague R, Parr IB and Haynes BP (1990fe) Metabolism of 4-iodo derivative of tamoxifen by isolated rat hepatocytes. Biochem Pharmacol 40: 2277-2283
19. McGuire \VL (1978) Hormone receptors; their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5: 428-433
20. Murphy CS, Langan FS, McCague R and Jordan VC (1990) Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responstve T47D breast cancer cells in vitro. Mol Pharmacol 38: 737-743
21. Osborne CK, Hobbs K and Clark GM (1985) Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 45:584-590
22. Osborne CK, Coronado E, Allred DC, Wiebe V and DeGregorio M (1991) Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerisation of trans-4-hydroxytamoxifen. J Nail Cancer InsI 83: 1477-1482
23. Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SO and Wakeling AE (1994) The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Cheinother Pharmacol 34: 89-95
24. Osbome CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL and Nicholson RI (1995) Comparison of the effects of a pure steroidal antiestrogen with those of lamoxifen in a model of human breast cancer. J Natl Cancer Inst 87: 746-750
25. Sutherland RL, Green MD, Hall RD, Reddell RR and Taylor IW (I983) Tamoxifen induces accumulation of MCF-7 human mammary carcinoma cells in the GO/G1 phase of the cell cycle. Ear J Cancer Clin Oncol 19: 615-621
26. Wiebe VJ, Osbome CK, McGuire WL and DeGregorio M W (1992) Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol 10:990-994
27. Wolf DM, Langhan-Fahey SM, Parker CJ, McCague R and Jordan VC (1993) Investigation of the mechanism of yamoxifen-stimulated breast tumor growth with nonisomerisable analogues of tamoxifen and metabolites. J Natl Cancer Inst 85: 806-812